Centene Corporation (CNC, NYSE) Posts Board And Operational Moves Amid Near-Term Momentum Fade

Centene entered a phase of operational adjustment in late June–August 2026 as leadership changes and state contract awards surfaced; near-term market momentum shows weakening even as fundamental cash flow and revenue expansion support a valuation gap.

Recent News

On August 13, 2026 Centene announced a planned chief financial officer transition. On July 10, 2026 the company reported changes to its board of directors. On June 24, 2026 a Centene subsidiary secured an Illinois Medicaid contract. Several subsidiary community and program investments and grants appeared across late June–August 2026.

Technical Analysis

Directional indicators conflict: DI+ shows an increasing trend (bullish signal) while DI- recorded a dip-and-reversal (bearish signal); ADX at 12.38 classifies the move as lacking trend strength, implying range-bound near-term price action that leaves valuation-driven catalysts as primary directional drivers.

MACD displays a peak-and-reversal pattern with MACD at 0.23 below the signal line at 0.25, signaling bearish momentum development and reducing the likelihood of sustained upside until momentum re-accelerates.

MRO at 20.53 registers positive, indicating price sits above the model target and that downward pressure into the coming weeks represents the higher-probability path for mean reversion toward fair value levels.

RSI sits at 53.2 but shows a peak-and-reversal, reflecting fading buying pressure despite a neutral absolute reading; that combination favors consolidation or modest pullback rather than continued trend extension.

Price sits above short- and long-term averages—price close $66.42 exceeds the 20-day ($65.62), 50-day ($65.49) and 200-day ($50.92) averages—yet the 12-day EMA shows a peak-and-reversal, and the close trades just under the 1x Bollinger upper band, which points to limited immediate upside without renewed momentum. SuperTrend support near $62.92 offers a technical reference for the current short-term structure.

 


Fundamental Analysis

Top-line and cash flow: Revenue rose materially year-over-year, with YoY revenue growth of 59.89% and QoQ revenue growth of 15.54%, while operating cash flow reached $3.59 billion and free cash flow totaled $3.416 billion; free cash flow yield equals 11.49%, a level that supports the view that the market undervalues available cash generation relative to the company’s price.

Profitability and margins: Operating margin stands at 2.24% and EBIT margin at 3.06%; both margins contracted QoQ (EBIT margin QoQ -32.49%) and EBIT margin fell YoY by 18.19%. Centene’s EBIT margin sits below the industry peer mean of 7.462% and below the industry peer median of 4.462%, indicating margin pressure relative to typical peer performance even as revenue expands.

Returns and leverage: Return on equity equals 4.84%, which exceeds the industry peer mean and sits above the industry peer median return on equity, showing modest equity returns. Debt-to-EBITDA equals 8.31x, a materially elevated leverage multiple, while debt-to-assets equals 19.40% and interest coverage stands at 10.71x, implying interest obligations remain serviceable but leverage sits toward the high end of operating-serviceable ranges.

Earnings and surprises: EPS ran $2.51 versus an estimate of $1.08, producing a $1.43 upside and an EPS surprise of roughly +132.4%. Despite the upside, earnings growth metrics show strain—earnings growth stands at -25.52% and YoY earnings growth at -78.30%—reflecting volatile year-over-year comparisons even as current-period earnings exceeded expectations.

Balance sheet and liquidity: Cash and short-term investments total $27.06 billion and cash conversion remains strong, with a cash conversion ratio of 9.04 and a cash conversion cycle slightly negative (≈ -3.83 days), supporting operational liquidity. Capital expenditures remain modest relative to revenue, while asset turnover at 0.6527 improved YoY and QoQ.

Valuation context: WMDST values the stock as under-valued. Current market price $66.42 compares with a price-target mean of $72.77 and an enterprise multiple of ~9.68x; the combination of strong free cash flow yield and stretched leverage frames the valuation gap as a function of margin and earnings volatility rather than cash-generation shortfall.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-06-30
REPORT DATE: 2026-07-28
NEXT REPORT DATE: 2026-10-27
CASH FLOW  Begin Period Cash Flow 21.4 B
 Operating Cash Flow 3.6 B
 Capital Expenditures -174.00 M
 Change In Working Capital 2.1 B
 Dividends Paid
 Cash Flow Delta 2.9 B
 End Period Cash Flow 24.3 B
 
INCOME STATEMENT REVENUE
 Total Revenue 53.6 B
 Forward Revenue 8.1 B
COSTS
 Cost Of Revenue 49.0 B
 Depreciation 139.0 M
 Depreciation and Amortization 300.0 M
 Research and Development
 Total Operating Expenses 52.4 B
PROFITABILITY
 Gross Profit 4.6 B
 EBITDA 1.9 B
 EBIT 1.6 B
 Operating Income 1.2 B
 Interest Income
 Interest Expense 153.0 M
 Net Interest Income -153.00 M
 Income Before Tax 1.5 B
 Tax Provision 399.0 M
 Tax Rate 26.9 %
 Net Income 1.1 B
 Net Income From Continuing Operations 1.1 B
EARNINGS
 EPS Estimate 1.08
 EPS Actual 2.51
 EPS Difference 1.43
 EPS Surprise 132.407 %
 Forward EPS 1.33
 
BALANCE SHEET ASSETS
 Total Assets 83.0 B
 Intangible Assets 15.0 B
 Net Tangible Assets 7.5 B
 Total Current Assets 46.7 B
 Cash and Short-Term Investments 27.1 B
 Cash 24.2 B
 Net Receivables 18.1 B
 Inventory
 Long-Term Investments 2.9 B
LIABILITIES
 Accounts Payable 18.0 B
 Short-Term Debt 75.0 M
 Total Current Liabilities 40.8 B
 Net Debt
 Total Debt 16.1 B
 Total Liabilities 60.4 B
EQUITY
 Total Equity 22.6 B
 Retained Earnings 11.3 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 45.67
 Shares Outstanding 493.987 M
 Revenue Per-Share 108.46
VALUATION
 Market Capitalization 29.7 B
 Enterprise Value 18.8 B
 Enterprise Multiple 9.682
Enterprise Multiple QoQ 113.768 %
Enterprise Multiple YoY -87.636 %
Enterprise Multiple IPRWA high: 87.909
mean: 34.57
median: 32.178
CNC: 9.682
low: -86.959
 EV/R 0.35
CAPITAL STRUCTURE
 Asset To Equity 3.679
 Asset To Liability 1.375
 Debt To Capital 0.417
 Debt To Assets 0.194
Debt To Assets QoQ -3.803 %
Debt To Assets YoY -4.64 %
Debt To Assets IPRWA high: 0.93
mean: 0.38
median: 0.301
CNC: 0.194
low: 0.006
 Debt To Equity 0.714
Debt To Equity QoQ -6.574 %
Debt To Equity YoY 11.296 %
Debt To Equity IPRWA high: 2.844
mean: 0.887
median: 0.748
CNC: 0.714
low: -1.417
PRICE-BASED VALUATION
 Price To Book (P/B) 1.318
Price To Book QoQ 48.748 %
Price To Book YoY 105.646 %
Price To Book IPRWA high: 15.571
mean: 2.251
median: 1.767
CNC: 1.318
low: -0.408
 Price To Earnings (P/E) 23.974
Price To Earnings QoQ 109.344 %
Price To Earnings YoY -126.209 %
Price To Earnings IPRWA high: 152.36
mean: 47.716
median: 45.322
CNC: 23.974
low: -81.789
 PE/G Ratio -0.939
 Price To Sales (P/S) 0.555
Price To Sales QoQ 46.0 %
Price To Sales YoY 54.013 %
Price To Sales IPRWA high: 11.857
mean: 2.5
median: 1.655
CNC: 0.555
low: 0.097
FORWARD MULTIPLES
Forward P/E 42.333
Forward PE/G -1.659
Forward P/S 3.755
EFFICIENCY OPERATIONAL
 Operating Leverage -3.789
ASSET & SALES
 Asset Turnover Ratio 0.653
Asset Turnover Ratio QoQ 3.186 %
Asset Turnover Ratio YoY 16.117 %
Asset Turnover Ratio IPRWA high: 1.051
CNC: 0.653
median: 0.419
mean: 0.412
low: 0.106
 Receivables Turnover 2.857
Receivables Turnover Ratio QoQ 7.361 %
Receivables Turnover Ratio YoY 28.935 %
Receivables Turnover Ratio IPRWA high: 7.49
mean: 3.724
median: 3.304
CNC: 2.857
low: 0.429
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 31.935
CASH CYCLE
 Cash Conversion Cycle Days (CCC) -3.834
Cash Conversion Cycle Days QoQ -178.591 %
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 133.289
median: 17.698
mean: 11.545
CNC: -3.834
low: -106.668
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 9.041
 CapEx To Revenue -0.003
 CapEx To Depreciation -1.252
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 38.6 B
 Net Invested Capital 38.7 B
 Invested Capital 38.7 B
 Net Tangible Assets 7.5 B
 Net Working Capital 5.9 B
LIQUIDITY
 Cash Ratio 0.664
 Current Ratio 1.145
Current Ratio QoQ 1.952 %
Current Ratio YoY 4.322 %
Current Ratio IPRWA high: 2.421
CNC: 1.145
mean: 1.055
median: 0.934
low: 0.278
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 8.306
 Cost Of Debt 0.689 %
 Interest Coverage Ratio 10.712
Interest Coverage Ratio QoQ -22.367 %
Interest Coverage Ratio YoY -2193.251 %
Interest Coverage Ratio IPRWA high: 26.066
CNC: 10.712
mean: 6.282
median: 6.254
low: -9.603
 Operating Cash Flow Ratio 0.095
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 35.768
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 2.263 %
 Revenue Growth 7.278 %
Revenue Growth QoQ 1554.091 %
Revenue Growth YoY 59.886 %
Revenue Growth IPRWA high: 17.804 %
CNC: 7.278 %
median: 3.075 %
mean: 1.498 %
low: -6.05 %
 Earnings Growth -25.519 %
Earnings Growth QoQ -93.34 %
Earnings Growth YoY -78.298 %
Earnings Growth IPRWA high: 108.333 %
median: 0.389 %
mean: -3.101 %
CNC: -25.519 %
low: -112.5 %
MARGINS
 Gross Margin 8.587 %
Gross Margin QoQ -22.834 %
Gross Margin YoY 42.028 %
Gross Margin IPRWA high: 96.512 %
mean: 29.468 %
median: 14.844 %
CNC: 8.587 %
low: 7.168 %
 EBIT Margin 3.059 %
EBIT Margin QoQ -32.487 %
EBIT Margin YoY -1818.539 %
EBIT Margin IPRWA high: 25.559 %
mean: 7.462 %
median: 4.462 %
CNC: 3.059 %
low: -12.904 %
 Return On Sales (ROS) 2.236 %
Return On Sales QoQ -39.989 %
Return On Sales YoY -370.375 %
Return On Sales IPRWA high: 23.787 %
mean: 8.284 %
median: 4.433 %
CNC: 2.236 %
low: -12.904 %
CASH FLOW
 Free Cash Flow (FCF) 3.4 B
 Free Cash Flow Yield 11.492 %
Free Cash Flow Yield QoQ -47.647 %
Free Cash Flow Yield YoY 27.945 %
Free Cash Flow Yield IPRWA CNC: 11.492 %
high: 6.209 %
mean: 2.03 %
median: 1.947 %
low: -4.3 %
 Free Cash Growth -18.003 %
Free Cash Growth QoQ -101.023 %
Free Cash Growth YoY -222.544 %
Free Cash Growth IPRWA high: 293.51 %
median: 23.352 %
CNC: -18.003 %
mean: -35.744 %
low: -972.093 %
 Free Cash To Net Income 3.131
 Cash Flow Margin 7.23 %
 Cash Flow To Earnings 3.551
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.329 %
Return On Assets QoQ -31.916 %
Return On Assets YoY -555.137 %
Return On Assets IPRWA high: 4.836 %
mean: 1.507 %
CNC: 1.329 %
median: 1.176 %
low: -2.927 %
 Return On Capital Employed (ROCE) 3.879 %
 Return On Equity (ROE) 0.048
Return On Equity QoQ -32.759 %
Return On Equity YoY -623.944 %
Return On Equity IPRWA high: 0.177
CNC: 0.048
median: 0.037
mean: -0.011
low: -0.286
 DuPont ROE 4.96 %
 Return On Invested Capital (ROIC) 3.099 %
Return On Invested Capital QoQ -29.408 %
Return On Invested Capital YoY -2125.49 %
Return On Invested Capital IPRWA high: 7.881 %
mean: 3.236 %
CNC: 3.099 %
median: 2.555 %
low: -5.362 %

Six-Week Outlook

Expect a near-term consolidation window driven by weakening momentum signals (MACD peak-and-reversal, RSI peak-and-reversal, positive MRO indicating mean-reversion risk). Structural supports include price remaining above the 50-day and 200-day averages, while momentum indicators must re-accelerate to validate renewed upside toward the WMDST price-target mean. Monitor MACD crossing back above its signal, a falling MRO reading, and recovery in short-term EMAs as the primary technical confirmation set for a reversion to higher implied valuation; absent those, range-bound action with downside bias toward short-term support is the higher-probability path over the next six weeks.

About Centene Corporation

Centene Corporation (NYSE:CNC) delivers comprehensive healthcare services, primarily targeting under-insured and uninsured populations across the United States. Established in 1984 and based in St. Louis, Missouri, Centene develops a wide array of health plans through its Medicaid, Medicare, and Commercial segments. The Medicaid segment offers expanded health plans, children’s health insurance programs, and long-term services. In the Medicare segment, Centene addresses the needs of seniors with special needs plans, Medicare supplements, and prescription drug plans. The Commercial segment provides marketplace insurance products for individuals and businesses, ensuring extensive access to healthcare services. Centene actively participates in government healthcare contracts, including the TRICARE program for military families, highlighting its dedication to diverse communities. The company also manages clinical healthcare services, pharmacies, and provides dental and speech therapy, promoting a holistic healthcare approach. By collaborating with primary and specialty care physicians, hospitals, and ancillary providers, Centene aims to deliver personalized, high-quality care to millions of Americans, emphasizing innovation and community well-being.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.